SCHEDULE 13G/A: Baker Bros. Maintains 9.95% Stake in Immatics N.V.

Baker Bros. Advisors and its affiliates have disclosed an unchanged 9.95% beneficial ownership stake in Immatics N.V., totaling 12,094,094 ordinary shares.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") have filed an Amendment No. 5 to their Schedule 13G for Immatics N.V.
• The Reporting Persons beneficially own an aggregate of 12,094,094 ordinary shares of Immatics N.V.
• This ownership represents 9.95% of the outstanding ordinary shares of Immatics N.V.
• The beneficial ownership is primarily held through Baker Brothers Life Sciences, L.P. (11,117,305 shares or 9.15%) and 667, L.P. (976,789 shares or 0.8%).
• The percentage of beneficial ownership is based on 121,559,507 shares of Common Stock outstanding as of June 30, 2025, as reported in Immatics N.V.'s 6-K filed on August 13, 2025.
• The Reporting Persons have sole voting and sole dispositive power over all 12,094,094 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The continued significant ownership by a reputable life sciences investor like Baker Bros. Advisors is generally viewed positively, indicating confidence in the company's prospects. The filing itself is a routine disclosure, but the underlying ownership is a positive signal.

Positives

• Continued significant investment by Baker Bros. Advisors, a prominent life sciences investor, signals confidence in Immatics N.V.'s long-term prospects.
• The substantial 9.95% stake provides a stable shareholder base and potential for strategic guidance from an experienced biotech investor.

Risks

• Concentration of ownership: A significant portion of the company's shares is held by a single investment group, which could influence corporate decisions.
• Potential for future divestment: While currently held for investment, any future decision by Baker Bros. to significantly reduce its stake could impact share price.

Future Outlook

Not applicable, as this filing is a disclosure of current ownership, not forward-looking statements from the issuer.

Industry Context

Baker Bros. Advisors is a well-known investment firm specializing in the life sciences sector. Their continued significant stake in Immatics N.V., a biotechnology company, aligns with their investment strategy in innovative biopharmaceutical firms. This indicates continued institutional interest in the biotech space, particularly in companies like Immatics N.V. that are developing novel therapies.

Comparison to Industry Standards

• Baker Bros. Advisors is a prominent institutional investor in the biotechnology and life sciences sector, known for taking significant, long-term positions in companies like Immatics N.V.
• Their investment strategy often involves identifying promising early to mid-stage biotech companies, similar to their historical investments in companies such as Seattle Genetics (now Seagen) and Incyte.
• A 9.95% stake is a substantial position for an institutional investor, often indicative of a high-conviction investment, aligning with the typical large stakes Baker Bros. takes in its portfolio companies.

Stakeholder Impact

• Shareholders: The continued significant stake by Baker Bros. may instill confidence among other shareholders, suggesting a strong institutional backing. It could also imply potential for Baker Bros. to exert influence on strategic decisions.
• Management: Management of Immatics N.V. will likely continue to engage with Baker Bros. as a major shareholder, potentially seeking their input on strategic direction.

Key Dates

Recommendation

This filing is a routine update on a significant existing ownership stake by a major institutional investor. It does not introduce new financial performance data or strategic changes from the company itself. While the continued large stake by Baker Bros. is a positive signal of their confidence, it doesn't fundamentally alter the investment thesis for Immatics N.V. based solely on this disclosure. Therefore, a "hold" recommendation is appropriate for investors who already have a position, awaiting further operational or financial updates from Immatics N.V. New investors would need to conduct further due diligence beyond this ownership disclosure.

Keywords

Immatics N.V., Baker Bros. Advisors, Schedule 13G, beneficial ownership, ordinary shares, institutional investment, biotechnology, life sciences, equity stake